Cargando…

Increased retention of tau PET ligand [(18)F]-AV1451 in Alzheimer’s Disease Psychosis

Psychosis in Alzheimer’s disease (AD) represents a distinct disease subtype with a more rapid progression of illness evidenced by an increased velocity of cognitive decline and a hastened mortality. Previous biomarker and post-mortem studies have implicated tau neuropathology as a possible mediator...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomar, J. J., Tan, G., Halpern, J., Gordon, M. L., Greenwald, B., Koppel, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881582/ https://www.ncbi.nlm.nih.gov/pubmed/35217635 http://dx.doi.org/10.1038/s41398-022-01850-z

Ejemplares similares

An updated radiosynthesis of [(18)F]AV1451 for tau PET imaging
por: Mossine, Andrew V., et al.
Publicado: (2017)

Quantification of Tau Load Using [(18)F]AV1451 PET
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Tsai, Richard M., et al.
Publicado: (2019)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

An autoradiographic evaluation of AV-1451 Tau PET in dementia
por: Lowe, Val J., et al.
Publicado: (2016)

In vivo retention of (18)F-AV-1451 in corticobasal syndrome
por: Smith, Ruben, et al.
Publicado: (2017)

Considerations and code for partial volume correcting [(18)F]-AV-1451 tau PET data
por: Baker, Suzanne L., et al.
Publicado: (2017)

Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2018)

Imaging Aβ and tau in early stage Alzheimer’s disease with [(18)F]AV45 and [(18)F]AV1451
por: Firouzian, Azadeh, et al.
Publicado: (2018)

(18)F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
por: Smith, Ruben, et al.
Publicado: (2016)

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

[(18)F]AV‐1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation
por: Bevan Jones, W. Richard, et al.
Publicado: (2016)

Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer’s Tauopathy
por: Murugan, N. Arul, et al.
Publicado: (2021)

(18)F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy
por: Passamonti, Luca, et al.
Publicado: (2017)

Quantitative (18)F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients
por: Zhao, Qian, et al.
Publicado: (2019)

MAPT rs242557 variant is associated with hippocampus tau uptake on (18)F-AV-1451 PET in non-demented elders
por: Shen, Xue-Ning, et al.
Publicado: (2019)

Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [(18)F]-AV-1451 PET data
por: Young, Christina B., et al.
Publicado: (2021)

(18)F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy
por: Nicastro, Nicolas, et al.
Publicado: (2019)

Deep learning application for the classification of Alzheimer’s disease using (18)F-flortaucipir (AV-1451) tau positron emission tomography
por: Park, Sang Won, et al.
Publicado: (2023)

The Role of 18F-Flortaucipir (AV-1451) in the Diagnosis of Neurodegenerative Disorders
por: Roy, Saswata, et al.
Publicado: (2021)

Cerebral [(18) F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy
por: Dickstein, D L, et al.
Publicado: (2016)

Imaging tau burden in dementia with Lewy bodies using [(18)F]-AV1451 positron emission tomography
por: Mak, Elijah, et al.
Publicado: (2021)

(18)F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
por: Smith, Ruben, et al.
Publicado: (2018)

Sex modulates the ApoE ε4 effect on brain tau deposition measured by (18)F-AV-1451 PET in individuals with mild cognitive impairment
por: Liu, Min, et al.
Publicado: (2019)

AV‐1451 tau and β‐amyloid positron emission tomography imaging in dementia with Lewy bodies
por: Kantarci, Kejal, et al.
Publicado: (2016)

Molecular pathology and synaptic loss in primary tauopathies: an (18)F-AV-1451 and (11)C-UCB-J PET study
por: Holland, Negin, et al.
Publicado: (2021)

Increased basal ganglia binding of (18) F‐AV‐1451 in patients with progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

(18)F‐AV‐1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy
por: Nedelska, Zuzana, et al.
Publicado: (2019)

[(18)F]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series
por: Marquié, Marta, et al.
Publicado: (2019)

[(18)F]-AV-1451 binding in the substantia nigra as a marker of neuromelanin in Lewy body diseases
por: Mak, Elijah, et al.
Publicado: (2021)

[(18)F]FDG, [(11)C]PiB, and [(18)F]AV-1451 PET Imaging of Neurodegeneration in Two Subjects With a History of Repetitive Trauma and Cognitive Decline
por: Okonkwo, David O., et al.
Publicado: (2019)

Increased Uptake of AV-1451 in a Subacute Infarction Lesion
por: Cho, Soo Hyun, et al.
Publicado: (2018)

[(18)F]AV‐1451 binding is increased in frontotemporal dementia due to C9orf72 expansion
por: Bevan‐Jones, Richard W., et al.
Publicado: (2018)

Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case
por: Marquié, Marta, et al.
Publicado: (2017)

Binding of [(18)F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients
por: Schaeverbeke, Jolien, et al.
Publicado: (2019)

[(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia
por: Bevan-Jones, W R, et al.
Publicado: (2018)

Optimal treatment of Alzheimer’s disease psychosis: challenges and solutions
por: Koppel, Jeremy, et al.
Publicado: (2014)

Evaluation of the early-phase [(18)F]AV45 PET as an optimal surrogate of [(18)F]FDG PET in ageing and Alzheimer’s clinical syndrome
por: Vanhoutte, Matthieu, et al.
Publicado: (2021)

Brain network alterations in individuals with and without mild cognitive impairment: parallel independent component analysis of AV1451 and AV45 positron emission tomography
por: Li, Yuan, et al.
Publicado: (2019)

PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with (18)F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders
por: Siderowf, Andrew, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_46lh4nkvdpt1e84nkmiss8jkq3